Shares of Prestige Consumer (NYSE:PBH) were unchanged after the company reported Q1 results.
Quarterly Results
Earnings per share were up 32.56% over the past year to $1.14, which beat the estimate of $0.87.
Revenue of $269,181,000 rose by 17.34% year over year, which beat the estimate of $232,440,000.
Outlook
Prestige Consumer Healthcare raised FY22 EPS guidance from $3.58 to $3.90 and sales forecast from $957 million-$962 million to $1.045 billion or more.
Conference Call Details
Date: Aug 05, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/r7g63yha
Recent Stock Performance
52-week high: $53.88
52-week low: $32.20
Price action over last quarter: Up 15.36%
Company Description
Prestige Consumer Healthcare is an American company that distributes branded over-the-counter healthcare and household cleaning products to mass merchandisers, drugstores, convenience stores, supermarkets, and e-commerce channels. The firm’s major brands include BC/Goody’s, Chloraseptic, Clear Eyes, Compound W, Debrox, Dramamine, Fess, Fleet, Gaviscon, Hydralyte, Monistat, Nix, and Summer’s Eve. The company’s portfolio includes branded products in women’s health, gastrointestinal, analgesics, eye and ear care, dermatological products, oral care, skincare, sleep aids, and cough and cold. Prestige has customers in the United States, Canada, and Australia.
